The global companion animal vaccine market is expected to be driven by the growing rate of adoption of companion animals, including rabbits, dogs, cats, etc. Growth in the companion animal vaccines sector is propelled by economic development, associated increase in disposable income, and rise in pet ownership and expenditure on pet care. In recent years, some European countries have witnessed a significant increase in pet adoption. Pets or companion animals offer humans much needed interaction that offers social, medical, emotional and physical benefits. North America, Europe and Asia are expected to be key markets.
Continual research, innovations and development of safe, effective and quality vaccines have enhanced protection for pets and farm animals. These developments are expected to stimulate the global companion animal vaccine market. For example, in 2020, Boehringer Ingelheim announced the upcoming release of its Purevax® vaccine range for cats in 0.5 ml presentation. Due to the small volume, the new presentation of Purevax® would make cat vaccination more convenient, enabling a gentler immunization experience for feline patients. The Purevax® range sough to protect cats from contracting important infectious feline diseases including feline herpesvirus (FHV) and feline calicivirus (FCV), feline panleukopenia virus (FPV), chlamydia felis, feline leukemia virus (FeLV), and rabies.
In 2020, Boehringer Ingelheim introduced DiaTEC, a novel, proprietary purification technology for Ingelvac CircoFLEX®; Ingelvac CircoFLEX® was the first PCV2 vaccine capable of being freshly mixed with an M hyo vaccine to address two critical swine pathogens in one injection. With DiaTEC, Ingelvac CircoFLEX® became the first and only non-virucidal PCV2 vaccine for improved capabilities to be freshly mixed on farm. Since its launch, Ingelvac CircoFLEX® had been employed to protect 3 billion pigs in over 68 countries across the globe, based on vaccine sales. In 2021, Boehringer Ingelheim announced a multi-year partnership with PetMedix to develop novel and transformative companion animal antibody therapeutics using PetMedix’s proprietary Ky9™ platform.
In 2021, Merck Animal Health announced its intent to acquire the assets of LIC Automation Ltd. (“LICA”). LICA was a leader in automation and technology for the dairy industry. The move would complement Broad Merck Animal Health portfolio of medicines, vaccines and technology solutions.
In 2020, Merck Animal Health completed the acquisition of U.S. Rights to SENTINEL® brand of combination parasiticides for companion animals. The move would solidify Merck Animal Health’s position in the U.S. companion animal category with comprehensive and continuous parasite protection, and complements the company’s broad portfolio of vaccines and pharmaceuticals.
Key Findings of the Report:
Market Analysis by Technology, Animal Type, Disease, Distribution Channel and Region:
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.